Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,583 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Macular Edema
Interventions
RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
Genetic · Biological
Lead sponsor
Sierra Eye Associates
Other
Eligibility
25 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Completed Phase 2 Interventional Results available

Pioglitazone in Early Parkinson's Disease

NCT01280123
Conditions
Parkinson's Disease
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Conditions
End-stage Renal Disease
Interventions
Intradialysis-yoga, Educational program
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Endometrial Cancer, Cervical Cancer, Vaginal Stricture, Radiation Toxicity
Interventions
Silicone Dilator, Standard Dilator
Device
Lead sponsor
Margaret Liotta
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Obesity, Childhood
Interventions
HALO, Enhanced Standard of Care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Psoriasis
Interventions
Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Conditions
Acquired Brain Injury, Stroke, Hemispatial Neglect
Interventions
Tonic and Phasic Attention Training, Active Comparator
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
21 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Tezacaftor/Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
Conditions
Dementia
Interventions
Health System-based Dementia Care, Community-based Dementia Care, Usual Care
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Wilkes-Barre, Pennsylvania • Galveston, Texas + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

NCT02691702
Conditions
Healthy Adult Subjects, Healthy Elderly Subjects
Interventions
BIIB118, Melatonin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida
Conditions
Idiopathic Hypersomnia
Interventions
Serdexmethylphenidate, Placebo
Drug · Other
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
Conditions
Control of Frontal Plane Biomechanics, Patellofemoral Pain Syndrome
Interventions
Hip Activation, Hip activation + Single leg balance
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Shreveport, Louisiana
Conditions
Psychotic Disorders
Interventions
Electronic Screen + Education (Phase 1), Targeted Provider Education (Phase 1), Community Mobile Engagement (Phase 2), Clinic based Engagement (Phase 2)
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
Epilepsy, Refractory Epilepsy, Music
Interventions
Experimental Intervention (Music A), Active Comparator Intervention (Music B), Active Comparator Intervention (Music C)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Worcester, Massachusetts • Lebanon, New Hampshire
Conditions
Deep Full-thickness Burn Injury (Disorder)
Interventions
realSKIN (skin xenotransplant), Human Cadaver Allograft
Biological
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Augusta, Georgia • Boston, Massachusetts
Conditions
Post-Traumatic Headache
Interventions
AMMO PTH DTx, AMMO SHAM
Device
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Skin Infection, Bacterial Infection
Interventions
Daptomycin, Brilacidin
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 1 more
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

NCT03431831
Conditions
Obesity
Interventions
Intervention Control, Counselling, Contrave, Contrave and Counseling
Behavioral · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Scottsbluff, Nebraska
Conditions
Intimate Partner Violence, Depression, Post Traumatic Stress Disorder
Interventions
MOSAIC Plus, MOSAIC
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Flint, Michigan
Conditions
Food Allergy in Children, Food Allergy
Interventions
use of virtual reality, use of standard technology
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
BIBW 2992, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
18
States / cities
Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more